Adherence to long-term adjuvant hormonal therapy for breast cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 6, 2011, Pages 709-715

  Gotay, Carolyn ^a   Dunn, Julia ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

adherence; aromatase inhibitors; breast cancer; tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ACCESS TO INFORMATION; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SELF ADMINISTRATION; HEALTH BELIEF; HOT FLUSH; HUMAN; INTRADUCTAL CARCINOMA; MOOD DISORDER; MYALGIA; OSTEOLYSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACEUTICAL CARE; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUPPORT GROUP;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MEDICATION ADHERENCE; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 81755177501     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.80     Document Type: Review

References (38)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Canadian Cancer Society. Toronto, ON, Canada (2011).
2. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev. Endocr. Metab. Disord. 8(3), 229-239 (2007).
3. Jordan C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2(3), 205-213 (2003).
4. Jordan C. Tamoxifen (IC146, 474) as a targeted therapy to treat and prevent breast cancer. Br. J. Pharmacol. 147(Suppl. 1), S269-S276 (2006).
5. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169), 1993-2000 (1999).
6. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res. Treat. 76(1), 27-36 (2002).
7. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90(18), 1371-1388 (1998).
8. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann. Oncol. 18(Suppl. 8), viii26- viii35 (2007).
9. Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J. Natl Compr. Canc. Netw. 4(10), 971-979 (2006).
10. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28(23), 3784-3796 (2010).
11. McCowan C, Shearer J, Donnan PT et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br. J. Cancer 99(11), 1763-1768 (2008).
12. Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res. Treat. 126(2), 529-537 (2011) .
13. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J. Clin. 59(1), 56-66 (2009).
14. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 71(1-2), 1-9 (2006).
15. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109(5), 832-839 (2007).
16. Cluze C, Rey D, Huiart L et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann. Oncol. doi:10.1093/annonc/mdr330 (2011) (Epub ahead of print).
17. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med. Care. 45(5), 431-439 (2007).
18. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J. Clin. Oncol. 27(21), 3445-3451 (2009).
19. Owusu C, Buist DS, Field TS et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J. Clin. Oncol. 26 (4), 549-555 (2008).
20. +) early stage breast cancer: a population based study from British Columbia. Cancer Res. 69(24), 36 (2009).
21. Hershman DL, Kushi LH, Shao T et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J. Clin. Oncol. 28(27), 4120-4128 (2010).
22. Huiart L, Dell'Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br. J. Cancer 104, 1558-1563 (2011).
23. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res. Treat. 130(2), 681-689 (2011).
24. Neugut AI, Subar M, Wilde ET et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J. Clin. Oncol. 29(18), 2534-2542 (2011).
25. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J. Clin. Oncol. 26(4), 556-562 (2008).
26. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res. Treat. 125(1), 191-200 (2011).
27. Ziller V, Kalder M, Albert US et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 20(3), 431-436 (2009).
28. World Health Organization. Adherence to long-term therapies - evidence for action. WHO, Geneva, Switzerland (2003).
29. Garreau J, DeLaMelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am. J. Surg. 192(4), 496-498 (2006).
30. Winters L, Habin K, Flanagan J, Cashavelly BJ. "I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors. Clin. J. Oncol. Nurs. 14(3), 379-382 (2010).
31. Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin. Breast Cancer 8(2), 155-161 (2008).
32. Davidson B, Vogel V, Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. J. Support Oncol. 5(3), 139-143 (2007).
33. Miaskowski C, Shockney L, Chlebowski RT. Adherence to endocrine therapy for breast cancer. Clin. J. Oncol. Nurs. 12(2), 213-221 (2008).
34. Winkeljohn D. Adherence to oral cancer therapies: nursing interventions. Clin. J. Oncol. Nurs. 14(4), 461-466 (2010).
35. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res. Treat. 126(2), 295-310 (2011).
36. Levine AM, Richardson JL, Marks G et al. Compliance with oral drug therapy in patients with hematologic malignancy. J. Clin. Oncol. 5(9), 1469-1476 (1987).
37. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 296(21), 2563-2571 (2006).
38. Ell K, Vourlekis B, Xie B et al. Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation. Cancer 115(19), 4606-4615 (2009).